🇺🇸 RCUS — Arcus Biosciences, Inc.

Salud Compra fuerte
← Volver

Precio actual

19,31 USD

Máx. histórico

48,47

1807 días

Caída desde máximo

-60,16%

Rango 52 semanas

17,43 – 31,74

Variación hoy

+2,12%

Cierre anterior

18,91

Rango de hoy

18,60 – 19,61

Volumen hoy

2.076.185

Peor caída histórica

-85,83%

23/11/2021 → 04/04/2025

Aún sin recuperar

Volatilidad anualizada ⓘ

75,61%

Información
Nombre completo
Arcus Biosciences, Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Biotechnology
Empleados
601
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
41,00 USD (puede no estar actualizado)
Primera cotización
15/03/2018
Precio actualizado
hace 13 horas
Sobre la empresa

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
10/02/2021 40,14 40,40 37,90 38,50 -3,65% 6,22% 513.000
09/02/2021 41,48 42,36 39,67 39,96 -3,45% 6,49% 276.500
08/02/2021 41,14 42,07 40,74 41,39 +2,20% 3,23% 451.200
05/02/2021 40,02 41,42 39,30 40,50 +2,56% 5,30% 422.100
04/02/2021 39,10 41,10 39,01 39,49 +1,54% 5,33% 580.700
03/02/2021 40,50 41,13 38,83 38,89 +0,36% 5,68% 429.300
02/02/2021 39,00 39,29 38,09 38,75 +1,49% 3,08% 524.900
01/02/2021 37,91 38,29 35,50 38,18 +9,93% 7,36% 522.500
29/01/2021 35,65 37,11 34,27 34,73 -1,92% 7,97% 291.500
28/01/2021 35,09 36,48 34,59 35,41 +2,40% 5,39% 286.600
27/01/2021 35,15 36,84 33,69 34,58 -4,02% 8,96% 616.300
26/01/2021 39,00 39,14 35,62 36,03 -5,66% 9,02% 392.600
25/01/2021 38,68 39,48 37,47 38,19 -0,57% 5,20% 390.700
22/01/2021 36,64 38,87 36,50 38,41 +3,67% 6,47% 388.700
21/01/2021 38,60 39,01 36,67 37,05 -4,07% 6,06% 420.400
20/01/2021 37,23 38,89 36,79 38,62 +5,15% 5,63% 558.700
19/01/2021 38,37 38,44 36,00 36,73 -0,68% 6,36% 469.700
15/01/2021 39,03 40,01 34,83 36,98 -4,76% 13,27% 939.500
14/01/2021 36,00 38,90 35,70 38,83 +8,83% 8,89% 998.000
13/01/2021 34,29 35,74 33,52 35,68 +5,22% 6,47% 485.900
12/01/2021 32,18 35,24 32,07 33,91 +5,74% 9,85% 543.300
11/01/2021 30,20 33,12 29,58 32,07 +4,02% 11,74% 486.500
08/01/2021 30,37 31,93 29,55 30,83 +2,53% 7,84% 557.100
07/01/2021 28,92 30,77 28,68 30,07 +3,76% 7,24% 462.900
06/01/2021 26,86 29,74 26,61 28,98 +8,54% 11,65% 950.400
05/01/2021 26,33 26,86 25,68 26,70 +2,06% 4,48% 418.000
04/01/2021 26,52 27,02 25,60 26,16 +0,77% 5,35% 577.700
31/12/2020 26,99 27,31 25,55 25,96 -4,38% 6,50% 544.100
30/12/2020 27,71 28,81 27,03 27,15 -1,42% 6,42% 505.100
29/12/2020 28,79 29,30 27,32 27,54 -3,47% 6,88% 344.600